Saturday 17 October 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.
21.72
0.80
−3.55%
Follow QURE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 4 | 5 | 4 |
+8 more TTM periods Free account |
| (157.61%) | (228.24%) | (207.10%) | (165.27%) | ||
| (32.13%) | (30.18%) | (28.81%) | (30.65%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(33.09%) | (36.74%) | (32.79%) | (37.27%) | |
Average Days of Receivables |
112.95 | 71.86 | 132.94 | 89.98 | |
Free Cash Flow per Share |
(2.44) | (2.75) | (3.10) | (2.62) | |
Free Cash Flow |
(161.45) | (172.56) | (178.40) | (153.60) | |
Capital Expenditures |
(0.66) | (0.45) | (0.44) | (0.36) | |
| Other line items | |||||
Cash ROIC |
(13.63%) | (21.96%) | (20.48%) | (15.76%) | |
Accounts Receivable Turnover |
3.28 | 5.95 | 2.74 | 3.42 | |
Accounts Payable Turnover |
0.27 | 0.35 | 0.27 | 0.32 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
1,296.24 | 940.07 | 1,119.25 | 1,215.63 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.03 | 0.03 | 0.03 | 0.05 | |
Research and Development Expense of Revenue |
708.49% | 739.01% | 873.85% | 918.86% | |
Selling, General and Administrative Expense of Revenue |
420.32% | 412.40% | 406.61% | 350.61% | |
Share Based Compensation of Revenue |
97.96% | 101.47% | 109.82% | 112.79% | |
Interest Coverage |
(3.35) | (3.15) | (2.99) | (2.89) | |
Operating CF/Net income |
0.64 | 0.82 | 0.89 | 0.65 | |
Depreciation/Fixed assets |
1.27 | 1.10 | 1.07 | 1.05 | |
Capex/Depreciation |
(0.05) | (0.03) | (0.03) | (0.02) | |
Revenue per Share |
0.28 | 0.29 | 0.28 | 0.27 | |
Operating CF per Share |
(2.43) | (2.74) | (3.09) | (2.62) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.02 |
Columns are period end dates